Enschede, 11^th April 2023

Solstice Pharmaceuticals is proud to announce the completion of our state-of-the-art cleanroom facilities for the clinical trial manufacturing of our cartridge system for monodisperse microbubbles. This is a significant milestone for our company and for the clinical translation of our cutting-edge technology.

Located in the Twente region, the new facilities will allow us to produce monodisperse microbubble cartridges in a controlled environment that meets the highest standards for cleanliness and sterility. This step is essential for ensuring the safety and efficacy of our products as we move forward with our clinical trajectory towards regulatory approval.

This initiative has been made possible with the support of the MedTech Fund, which recognises the potential of our technology to revolutionise the field of ultrasound imaging & therapeutics. We are grateful for their partnership and look forward to continuing our collaboration to bring this innovative technology to patients across the world.

"We are thrilled to have completed our GMP cleanroom facilities and to be moving forward with clinical trial manufacturing," said Dr Wim van Hoeve, Managing director of Solstice Pharmaceuticals. "This is a major step forward for our company and for the field of ultrasound imaging & therapeutics. Our next generation microbubbles have the potential to improve diagnosis and treatment for a wide range of medical applications from diagnostic ultrasound at the bedside to revolutionary drug delivery by opening the blood-brain barrier."

Solstice Pharmaceuticals is a leading innovator in the development of monodisperse microbubble technology for medical imaging & therapeutics. Our products are designed to improve the accuracy and sensitivity of ultrasound applications, enabling earlier detection and more effective treatment for a wide range of diseases.

For more information about Solstice Pharmaceuticals and our products, please visit our website at www.solsticepharma.com.

Contact:
Wim van Hoeve, Managing director
Solstice Pharmaceuticals
w.vanhoeve@solsticepharma.com
+31 53 2030410